Cautious Optimism for Qiagen Amidst Industry Challenges: Awaiting Long-term Growth Assurance

William Blair analyst Andrew Brackmann has maintained their neutral stance on QGEN stock, giving a Hold rating on May 9.

Andrew Brackmann’s rating is based on several factors, including Qiagen’s ability to manage revenue growth and profitability amidst challenging industry conditions. The management’s confidence in their outlook, particularly in the consumables business which constitutes a significant portion of their revenue, suggests that the company is on stable ground. However, there are concerns regarding external factors such as tariffs, competition, and research funding, which are being considered in future estimates.
Despite Qiagen’s efforts to position itself as a reliable and growing entity, the current valuation of 18 times next twelve months earnings seems to accurately reflect its short-term growth prospects. Brackmann seeks more assurance in the sustainability of revenue growth in the latter half of 2025 and into 2026, along with potential acceleration towards the company’s long-term growth targets, before considering an upgrade in the rating.

According to TipRanks, Brackmann is an analyst with an average return of -6.1% and a 32.00% success rate. Brackmann covers the Healthcare sector, focusing on stocks such as Qiagen, NeoGenomics, and QuidelOrtho.